Thereby these drugs destroy pre‐existing tumour blood vessels and cutting off the supply of oxygen and other nutrients required for tumour cell growth as well as inhibiting tumour neovascularization, which in turn inhibits the growth and metastasis of tumour cells and effectively improving the transport of chemotherapy drugs.13 The array of clinically useful angiogenic inhibitors is now expanding beyond the VEGF pathway to include inhibitors of placental growth factor, integrin and other molecules. The gene discussed is PGF; the disease is neoplasm.